AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Vaccines
i think what has to be taken into account, which is wy the halfe control groups. If you look, for example, if you get two doses of the ancestral strain and then you get a third dose of the ancestral strains, you clearly get a boost. So these numbers do not necessarily correlate efficacy. We're asking now for a logistic shift, where potentially billions of dollars are at stake without clear and compelling evidence that it's actually going to improve the outcome we care about most - protection against severe disease. And yet, it seems like the burden of proof for fda seems to be going down and down and down, instead of being at a level that you're comfortable with